Trastuzumab deruxtecan + Capecitabine + Paclitaxel + Nab-Paclitaxel
Phase 3Active 0 views this week 0 watching⚡ Active
Interest: 44/100
44
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Advanced or Metastatic Breast Cancer
Conditions
Advanced or Metastatic Breast Cancer
Trial Timeline
Jul 24, 2020 → Jun 19, 2026
NCT ID
NCT04494425About Trastuzumab deruxtecan + Capecitabine + Paclitaxel + Nab-Paclitaxel
Trastuzumab deruxtecan + Capecitabine + Paclitaxel + Nab-Paclitaxel is a phase 3 stage product being developed by Daiichi Sankyo for Advanced or Metastatic Breast Cancer. The current trial status is active. This product is registered under clinical trial identifier NCT04494425. Target conditions include Advanced or Metastatic Breast Cancer.
What happened to similar drugs?
16 of 20 similar drugs in Advanced or Metastatic Breast Cancer were approved
Approved (16) Terminated (1) Active (4)
Hype Score Breakdown
Clinical
17
Activity
12
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04494425 | Phase 3 | Active |
Competing Products
20 competing products in Advanced or Metastatic Breast Cancer